Pharvaris (NASDAQ:PHVS) CEO Sells $65,551.20 in Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $28.60, for a total value of $65,551.20. Following the completion of the sale, the chief executive officer directly owned 139,792 shares in the company, valued at $3,998,051.20. The trade was a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Berndt Modig also recently made the following trade(s):

• On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The shares were sold at an average price of $27.74, for a total value of $647,257.42.

Pharvaris Trading Up 1.2%

NASDAQ PHVS traded up $0.35 on Monday, hitting $28.93. The company’s stock had a trading volume of 88,705 shares, compared to its average volume of 170,640. The firm has a market cap of $1.89 billion, a P/E ratio of -8.57 and a beta of -2.58. Pharvaris N.V. has a 52-week low of $13.81 and a 52-week high of $29.89. The company’s 50-day simple moving average is $27.25 and its 200 day simple moving average is $25.68.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). On average, research analysts forecast that Pharvaris N.V. will post -2.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

A number of hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris during the 4th quarter valued at about $35,000. Barclays PLC purchased a new position in shares of Pharvaris during the fourth quarter valued at approximately $77,000. China Universal Asset Management Co. Ltd. bought a new position in Pharvaris during the third quarter valued at approximately $75,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Pharvaris in the fourth quarter worth approximately $86,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on PHVS shares. Wall Street Zen cut shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research note on Monday, April 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Wolfe Research assumed coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research report on Tuesday, March 3rd. Finally, Wedbush boosted their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and an average target price of $42.73.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.